Vertex comprará Alpine Immune Sciences por $4.9B em grande negócio de biotecnologia em Seattle.

# Boston-based Vertex Pharmaceuticals to Acquire Seattle’s Alpine Immune Sciences for $4.9 billion

Alpine Immune Sciences, a Seattle-based biotech company, is set to be acquired by Vertex Pharmaceuticals in a deal worth $4.9 billion. This acquisition marks a significant moment for both companies and holds promise for patients in need of innovative immunotherapies.

## A Premium Deal: Vertex’s Acquisition of Alpine

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $65 per share, representing a 38% premium over Alpine’s closing price. This deal comes after Alpine’s stock surged following reports of a potential sale, leading to a higher premium for shareholders.

Alpine specializes in developing immunotherapies for conditions such as cancer, kidney disease, and autoimmune disorders. One of their key products, povetacicept (ALPN-303), shows promise in treating autoimmune and inflammatory diseases and is expected to enter Phase 3 clinical trials later this year.

## A Promising Future for Alpine and Vertex

Mitchell Gold, CEO of Alpine Immune Sciences, expressed excitement about the acquisition, highlighting the potential benefits for patients and the company’s pipeline of products. With a background in biotech and healthcare investment, Gold brings valuable expertise to the table.

The acquisition by Vertex Pharmaceuticals is part of a trend of major deals in the biotech sector, particularly in the Seattle region. Both companies’ boards have approved the transaction, which is expected to close in the second quarter.

Alpine, which was founded in 2015 and went public in 2017, has made significant strides in the development of innovative therapies. With a dedicated team of researchers and professionals, the company has positioned itself as a leader in the biotech industry.

## Conclusion

The acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals represents a significant milestone in the biotech sector. With a focus on cutting-edge immunotherapies and a commitment to advancing patient care, both companies are poised for a successful partnership. Stay tuned for more updates on this groundbreaking deal.